Arcus Biosciences, Inc. (RCUS)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

30.49-0.81 (-2.59%)

At close: 4:00PM EDT

30.49 0.00 (0.00%)
After hours: 5:11PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	31.30
Open	31.29
Bid	28.61 x 800
Ask	38.00 x 1000
Day's Range	29.18 - 31.30
52 Week Range	15.03 - 42.36
Volume	487,528
Avg. Volume	535,183

Market Cap	2.161B
Beta (5Y Monthly)	1.08
PE Ratio (TTM)	N/A
EPS (TTM)	-2.24
Earnings Date	May 03, 2021 - May 07, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	53.20

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Business Wire
Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented progression-free survival (PFS) and overall survival (OS) data in patients with advanced metastatic colorectal cancer (mCRC) from the ARC-3 study at the 2021 American Association for Cancer Research (AACR) Annual Meeting. ARC-3 was a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study that evaluated the safety, tolerability, PK and early clinical activity of etrumadenant, the first dual adenosine A2a/A2b receptor antagonist in the clinic, in subjects with mCRC.
- Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021
  PR Newswire
- Harmony Biosciences To Present WAKIX® (Pitolisant) Data At The 2021 AAN Annual Meeting
  PR Newswire
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted twelve new employees options to purchase a total of 180,200 shares of the Company’s common stock at an exercise price per share of $30.90, which was the closing price on April 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
- GlobeX Data Issues Stock Options to Directors and Officers
  ACCESSWIRE
- Aztec Appoints Vice President, Exploration
  ACCESSWIRE
Simply Wall St.
Independent Director Kathryn Falberg Just Bought 12% More Shares In Arcus Biosciences, Inc. (NYSE:RCUS)
Arcus Biosciences, Inc. ( NYSE:RCUS ) shareholders (or potential shareholders) will be happy to see that the...